专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08034813B2 Polymorphs of brimonidine pamoate 有权
标题翻译：溴莫尼定双羟萘酸的多晶型物
公开(公告)号：US08034813B2
公开(公告)日：2011-10-11
申请号：US12604427
申请日：2009-10-23
申请人： Hongna Wang , Stephen R. Davio , Gregory L. McIntire , Michael Hall , Shazad Suchit , Jon Summersett , Brent Whitehead
发明人： Hongna Wang , Stephen R. Davio , Gregory L. McIntire , Michael Hall , Shazad Suchit , Jon Summersett , Brent Whitehead
IPC分类号： A61K31/495
CPC分类号： B07C5/34 , A61K9/0019 , A61K31/498 , A61K47/10 , A61K47/183 , A61K47/32 , A61K47/38 , C07C51/41 , C07C65/11 , C07D403/12
摘要： A brimonidine (5-bromo-6-(2-imidazolidinylideneamino)quinoxaline) pamoate polymorph exhibits characteristics disclosed herein. The brimonidine pamoate polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.
摘要翻译：溴莫尼定（5-溴-6-（2-咪唑烷亚基氨基）喹喔啉）双羟萘酸盐多晶型物表现出本文公开的特征。溴莫尼定双羟萘酸盐多晶型物包括在组合物，装置或植入物中，用于治疗或控制升高的眼内压或神经保护神经组织的组分以防止这些组分的进行性退化。特别地，这样的组合物，装置或植入物可用于向视神经系统的细胞和组分提供神经保护。

2. 发明申请

US20120015951A1 Polymorphs of Brimonidine Pamoate 有权
标题翻译：溴莫尼定双羟萘酸的多晶型物
公开(公告)号：US20120015951A1
公开(公告)日：2012-01-19
申请号：US13233052
申请日：2011-09-15
申请人： Hongna Wang , Stephen R. Davio , Gregory L. McIntire , Michael Hall , Shazad Suchit , Jon Summersett , Brent Whitehead
发明人： Hongna Wang , Stephen R. Davio , Gregory L. McIntire , Michael Hall , Shazad Suchit , Jon Summersett , Brent Whitehead
IPC分类号： A61K31/498 , A61P27/06 , A61P25/28 , C07D241/42 , A61P25/00
CPC分类号： B07C5/34 , A61K9/0019 , A61K31/498 , A61K47/10 , A61K47/183 , A61K47/32 , A61K47/38 , C07C51/41 , C07C65/11 , C07D403/12
摘要： A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.
摘要翻译：溴莫尼定双羟萘酸盐多晶型物显示本文公开的特征。多晶型物包括在组合物，装置或植入物中，用于治疗或控制升高的眼内压或神经保护神经组织的组分以防止这些组分的逐渐退化。特别地，这样的组合物，装置或植入物可用于向视神经系统的细胞和组分提供神经保护。

3. 发明授权

US08420648B2 Polymorphs of brimonidine pamoate 有权
标题翻译：溴莫尼定双羟萘酸的多晶型物
公开(公告)号：US08420648B2
公开(公告)日：2013-04-16
申请号：US13233052
申请日：2011-09-15
申请人： Hongna Wang , Stephen R. Davio , Gregory L. McIntire , Michael Hall , Shazad Suchit , Jon Summersett , Brent Whitehead
发明人： Hongna Wang , Stephen R. Davio , Gregory L. McIntire , Michael Hall , Shazad Suchit , Jon Summersett , Brent Whitehead
IPC分类号： A61K31/495
CPC分类号： B07C5/34 , A61K9/0019 , A61K31/498 , A61K47/10 , A61K47/183 , A61K47/32 , A61K47/38 , C07C51/41 , C07C65/11 , C07D403/12
摘要： A brimonidine pamoate polymorph exhibits characteristics disclosed herein, wherein the brimonidine pamoate has the following formula The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.
摘要翻译：溴莫尼定双羟萘酸盐多晶型物显示了本文公开的特征，其中双酚A对苯二甲酸酯具有下列结构式多晶型物包括在组合物，装置或植入物中，用于治疗或控制升高的眼内压或神经保护神经组织的组分以防止这些组分的进行性退化。特别地，这样的组合物，装置或植入物可用于向视神经系统的细胞和组分提供神经保护。

4. 发明申请

US20100125077A1 Polymorphs of Brimonidine Pamoate 有权
标题翻译：溴莫尼定双羟萘酸的多晶型物
公开(公告)号：US20100125077A1
公开(公告)日：2010-05-20
申请号：US12604427
申请日：2009-10-23
申请人： Hongna Wang , Stephen R. Davio , Gregory L. McIntire , Michael Hall , Shazad Suchit , Jon Summersett , Brent Whitehead
发明人： Hongna Wang , Stephen R. Davio , Gregory L. McIntire , Michael Hall , Shazad Suchit , Jon Summersett , Brent Whitehead
IPC分类号： A61K31/498 , C07D241/42 , A61P27/02 , A61P25/00
CPC分类号： B07C5/34 , A61K9/0019 , A61K31/498 , A61K47/10 , A61K47/183 , A61K47/32 , A61K47/38 , C07C51/41 , C07C65/11 , C07D403/12
摘要： A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.
摘要翻译：溴莫尼定双羟萘酸盐多晶型物显示本文公开的特征。多晶型物包括在组合物，装置或植入物中，用于治疗或控制升高的眼内压或神经保护神经组织的组分以防止这些组分的逐渐退化。特别地，这样的组合物，装置或植入物可用于向视神经系统的细胞和组分提供神经保护。

5. 发明申请

US20080293728A1 Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions 审中-公开
标题翻译：包含α2-肾上腺素能受体激动剂和组合物的复合物
公开(公告)号：US20080293728A1
公开(公告)日：2008-11-27
申请号：US12121083
申请日：2008-05-15
申请人： Gregory L. McIntire , Stephen R. Davio , Arthur E. Harms , Hongna Wang
发明人： Gregory L. McIntire , Stephen R. Davio , Arthur E. Harms , Hongna Wang
IPC分类号： A61K31/498 , C07D403/12 , C07C55/20 , C07C57/03 , C07C65/10 , A61P25/00 , C07C65/05 , C07C229/36 , C07C61/29
CPC分类号： C07D403/12 , C07D498/04
摘要： A complex comprises at least an α2-adrenergic receptor agonist and a compound that provides an opposite charge to a charge on the α2-adrenergic receptor agonist, wherein the complex is charge neutral as a whole and has a solubility in a range from about 0.3 μg/ml to about 2.5 mg/ml in water at pH of about 7 and temperature of about 25° C. The complex is included in a composition, device, or implant for use in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.
摘要翻译：复合物包含至少一种α2-肾上腺素能受体激动剂和向α2-肾上腺素能受体激动剂上的电荷提供相反电荷的化合物，其中该络合物作为整体为电荷中性，并且在约0.3μm的范围内具有溶解度 / ml至约2.5mg / ml，pH约7，温度约25℃。该复合物包含在组合物，装置或植入物中，用于神经保护神经组织的组分以防止进行性退化的这些组件。特别地，这样的组合物，装置或植入物可用于向视神经系统的细胞和组分提供神经保护。

6. 发明申请

US20100104551A1 METHOD FOR PROLONGING ACTIVITY OF AUTODEGRADABLE ENZYMES AND COMPOSITIONS THEREOF 审中-公开
标题翻译：用于增强可自由可扩链酶活性的方法及其组合物
公开(公告)号：US20100104551A1
公开(公告)日：2010-04-29
申请号：US12603988
申请日：2009-10-22
申请人： Dharmendra M. Jani , Kai Kwok , Gregory L. McIntire , Bruce A. Pfeffer , Afshin Shafiee , Ruiwen Shi , Srini Venkatesh , Hongna Wang , Yan Huang , Stephen R. Davio
发明人： Dharmendra M. Jani , Kai Kwok , Gregory L. McIntire , Bruce A. Pfeffer , Afshin Shafiee , Ruiwen Shi , Srini Venkatesh , Hongna Wang , Yan Huang , Stephen R. Davio
IPC分类号： A61K38/48 , A61P27/02
CPC分类号： C12N9/50 , A61K31/198 , C12N9/6435 , C12N9/96 , C12Y304/21007
摘要： A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), γ-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-α-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives. The method is useful to provide enzyme for wide use, which otherwise would lose activity upon long storage. In one embodiment the method is applicable to provide enzyme for inducing controlled posterior vitreous detachment.
摘要翻译：长效酶的组合物包含在包含缓冲液和添加剂的制剂中的酶，所述缓冲剂和添加剂选自氨甲环酸，氨基己酸和除了氨甲环酸以外的L-赖氨酸和β-氨基己酸酸，其组合，及其混合物。所述组合物可以进一步包含选自L-赖氨酸，L-精氨酸，L-鸟氨酸（或其药学上可接受的盐，例如L-鸟氨酸盐酸盐），γ-氨基丁酸，5-氨基戊酸，7 氨基庚酸，甘氨酰甘氨酸，三甘氨酸，N-α-乙酰基-L-精氨酸，甜菜碱，肌氨酸，明胶，HSA，链激酶，tPA，uPA，非离子表面活性剂，甘油，D-山梨糖醇，其组合及其混合物。用于延长自动降解酶的活性的方法包括在低pH下制备后储存酶，并且在使用前将酸化酶与含有至少一种这样的添加剂的溶液重新组合。该方法对于提供广泛使用的酶是有用的，否则将在长期储存时失去活性。在一个实施方案中，该方法适用于提供用于诱导受控的后玻璃体脱离的酶。

7. 发明申请

US20110183946A1 Complexes Comprising alpha2-Adrenergic Receptor Agonists and Methods of Providing Neuroprotection or Treating or Inhibiting Progression of Glaucoma 审中-公开
标题翻译：包含α2-肾上腺素能受体激动剂的复合物和提供神经保护作用或治疗或抑制青光眼进展的方法
公开(公告)号：US20110183946A1
公开(公告)日：2011-07-28
申请号：US13078024
申请日：2011-04-01
申请人： Gregory L. McIntire , Stephen R. Davio , Arthur E. Harms , Hongna Wang
发明人： Gregory L. McIntire , Stephen R. Davio , Arthur E. Harms , Hongna Wang
IPC分类号： A61K31/498 , A61K31/60 , A61P25/00 , A61P27/06
CPC分类号： C07D403/12 , C07D498/04
摘要： A complex comprises at least an α2-adrenergic receptor agonist and a compound that provides an opposite charge to a charge on the α2-adrenergic receptor agonist, wherein the complex is charge neutral as a whole and has a solubility in a range from about 0.3 μg/ml to about 2.5 mg/ml in water at pH of about 7 and temperature of about 25° C. The complex is included in a composition, device, or implant for use in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system or to inhibit progression of damage to the optic nerve system resulting from glaucoma.
摘要翻译：复合物包含至少一种α2-肾上腺素能受体激动剂和向α2-肾上腺素能受体激动剂上的电荷提供相反电荷的化合物，其中该络合物作为整体为电荷中性，并且具有在约0.3μg / ml至约2.5mg / ml，pH约7，温度约25℃。该复合物包含在组合物，装置或植入物中，用于神经保护神经组织的组分以防止进行性退化的这些组件。特别地，这种组合物，装置或植入物可用于向视神经系统的细胞和组分提供神经保护，或抑制由青光眼引起的视神经系统损伤的进展。

8. 发明授权

US5716642A Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents 失效
标题翻译：使用衍生自相似药剂的表面活性物质微粒沉淀纳米颗粒药剂
公开(公告)号：US5716642A
公开(公告)日：1998-02-10
申请号：US370928
申请日：1995-01-10
申请人： Pranab Bagchi , Gregory L. McIntire , John R. Minter
发明人： Pranab Bagchi , Gregory L. McIntire , John R. Minter
IPC分类号： A61K9/14 , A61K49/04
CPC分类号： B82Y5/00 , A61K49/0428 , A61K9/146 , Y10S977/746 , Y10S977/881 , Y10S977/90 , Y10S977/915
摘要： This invention describes the preparation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in an alkaline solution and then neutralizing the said solution with an acid in the presence of suitable surface-modifying, surface-active agents to form a fine particle dispersion of the said pharmaceutical agent. A combination of surface active surface modifying agents comprising a nonionic surface active substance and an anionic surface active material having a chemical structure which is at least on a molecular basis 75% similar to the pharmaceutical agent is used. This process is preferably followed by steps of diafiltration clean-up of the dispersion and then concentration of it to a desired level. This process of dispersion preparation leads to microcrystalline particles of Z-average diameters smaller than 400 nm as measured by photon correlation spectroscopy. Various modifications of precipitation schemes are described, many of which are suitable for large-scale manufacture of these agent dispersions.
摘要翻译：本发明描述了纳米颗粒药剂分散体的制备方法，该方法包括将所述药剂溶解在碱性溶液中，然后在合适的表面改性表面活性剂存在下用酸中和所述溶液形成所述药剂的细颗粒分散体。使用包含非离子表面活性物质的表面活性表面改性剂和具有与药剂相似至少分子量为75％的化学结构的阴离子表面活性物质的组合。该方法优选的是通过渗滤清洁分散体的步骤，然后将其浓缩至期望的水平。这种分散制备过程导致通过光子相关光谱测量的Z平均直径小于400nm的微晶颗粒。描述了沉淀方案的各种改进，其中许多适用于这些试剂分散体的大规模生产。

9. 发明授权

US5352459A Use of purified surface modifiers to prevent particle aggregation during sterilization 失效
标题翻译：使用纯化的表面改性剂来防止灭菌过程中的颗粒聚集
公开(公告)号：US5352459A
公开(公告)日：1994-10-04
申请号：US991639
申请日：1992-12-16
申请人： Kenneth R. Hollister , David Ladd , Gregory L. McIntire , George C. Na , Natarajan Rajagopalan , Barbara O. Yuan
发明人： Kenneth R. Hollister , David Ladd , Gregory L. McIntire , George C. Na , Natarajan Rajagopalan , Barbara O. Yuan
IPC分类号： A61L2/00 , A61K9/14 , A61K47/30 , A61K47/34 , A61K49/04
CPC分类号： B82Y5/00 , A61K49/049 , A61K9/146 , Y10S514/951
摘要： This invention discloses a composition comprised of nanoparticles having a purified polymeric surfactant as a surface modifier adsorbed on the surface thereof and a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the cloud point of the surface modifier. Preferred purified polymeric surfactants are purified polyalkyleneoxide substituted ethylenediamine surfactants. A preferred cloud point modifier is polyethylene glycol. This invention further discloses a method of making nanoparticles having a purified polymeric surfactant as a surface modifier adsorbed on the surface and a cloud point modifier associated therewith, comprised of contacting said nanoparticles with the cloud point modifier for a time and under conditions sufficient to increase the cloud point of the surface modifier.
摘要翻译：本发明公开了一种组合物，其由具有作为吸附在其表面上的表面改性剂的纯化聚合物表面活性剂和与其相关联的浊点改性剂的纳米颗粒组成，该浊点改性剂以足以增加表面改性剂的浊点的量存在。优选的纯化聚合物表面活性剂是纯化的聚环氧烷取代的乙二胺表面活性优选的浊点改性剂是聚乙二醇。本发明还公开了一种制备具有纯化的聚合物表面活性剂作为吸附在表面上的表面改性剂和与之相关的浊点改性剂的纳米颗粒的方法，该方法包括将所述纳米颗粒与浊点改性剂接触一段时间并在足以增加浊点的表面改性剂。

10. 发明授权

US08165948B2 System for selecting and purchasing assets and maintaining an investment portfolio 有权
标题翻译：选择和购买资产和维持投资组合的制度
公开(公告)号：US08165948B2
公开(公告)日：2012-04-24
申请号：US12767266
申请日：2010-04-26
申请人： James P. O'Shaughnessy , Gregory L. Cowin , Stephen M. Downey , Gregory L. McIntire , Kevin P. Tyson
发明人： James P. O'Shaughnessy , Gregory L. Cowin , Stephen M. Downey , Gregory L. McIntire , Kevin P. Tyson
IPC分类号： G06Q40/00
CPC分类号： G06Q40/06 , G06Q20/102 , G06Q40/04 , G06Q40/10 , G06Q40/12
摘要： The invention is in the field of computer implemented systems and methods for generating a profile of an investor's risk tolerance, providing automated investment allocation advice based on the risk tolerance of the investor, generating at least one list of investments for the portfolio of the investor, allowing for review of the at least one list of investments and information relating to historic and/or hypothetical performance and a description of asset selection methodology, performing automated electronic execution of transactions pertaining the investments, maintenance and monitoring of investment portfolios, and rebalancing of investment portfolios.
摘要翻译：本发明在计算机实施的系统和方法领域中，用于产生投资者风险承受能力的简档，基于投资者的风险容忍度提供自动投资分配咨询，为投资者的投资组合生成至少一个投资清单，允许审查至少一个投资名单和与历史和/或假设性能有关的信息，以及资产选择方法的描述，执行与投资，维护和监督投资组合有关的交易的自动化电子执行以及投资重新平衡投资组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式